Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile-Reference-Cited by-同舟云学术

Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile

Published:2020-07-22 Issue:17 Volume:21 Page:2125-2135
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Muzurović Emir¹²,Mikhailidis Dimitri P³

Affiliation:

1. Department of Internal Medicine, Endocrinology Section, Clinical Center of Montenegro, Podgorica, Montenegro

2. University of Montenegro Faculty of Medicine, Podgorica, Montenegro

3. Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1795132

Reference135 articles.

1. Leptin, cardiovascular diseases and type 2 diabetes mellitus

2. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017

3. Cardiovascular disease prevention strategies for type 2 diabetes mellitus

4. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013

5. Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic Drugs;Diabetes Technology & Therapeutics;2024-09-01

2. Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation;Clinical Transplantation;2024-07

3. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy;Frontiers in Cardiovascular Medicine;2023-12-06

4. GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?;Journal of Diabetes and its Complications;2023-12

5. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists;Obesity Reviews;2023-11-15